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Summary. Background: Congenital thrombotic thrombo-
cytopenic purpura (TTP) is characterized by mutations in
the ADAMTS13 gene, which either impair protein secre-
tion or influence ADAMTS13 (A Disintegrin-like And
Metalloprotease domain with ThromboSpondin type-1
motif, member 13) activity. Phenotypic consequences of
these mutations have not yet been evaluated in animal
models for TTP. Objectives: To identify the in vitro effect
of a novel ADAMTS13 mutation and to investigate
whether this mutation induces TTP in vivo. Methods: All
29 ADAMTS13 exons with exon–intron boundaries of a
patient with pregnancy-onset TTP were sequenced. Wild-
type and mutant ADAMTS13 proteins were both tran-
siently and stably expressed in human embryonic kidney
cells, and their activity was evaluated in vitro using fluor-
escence resonance energy transfer and flow assays. Molec-
ular dynamics simulations were performed to study Ca2+
stability. Adamts13–/– mice were hydrodynamically
injected with wild-type and mutant expression plasmids
and triggered with recombinant human von Willebrand
factor. Results: We identified a novel heterozygous
c.559G>C mutation in exon 6 of the proposita’s ADAM-
TS13 gene. This mutation resulted in a p.Asp187His sub-
stitution (p.D187H), which was located in the high
affinity Ca2+-binding site in the metalloprotease domain
of ADAMTS13. The homozygous p.D187H mutation
down-regulated ADAMTS13 activity in vitro. Impaired
proteolytic activity was linked to unstable Ca2+ binding
as visualized using a molecular dynamics simulation. In
addition, the p.D187H mutation affects protein secretion
in vitro. In Adamts13–/– mice, the homozygous p.D187H
mutation reduced ADAMTS13 secretion and activity and
contributed to TTP when these mice were triggered with
recombinant human von Willebrand factor. Conclusions:
Our data indicate that the p.D187H mutation impairs
ADAMTS13 activity and secretion and is responsible for
TTP onset in mice.
Keywords: ADAMTS13 protein, human; ADAMTS13
protein, mouse; animal model; mutation; thrombotic
thrombocytopenic purpura.
Introduction
When patients are deficient in the metalloprotease
ADAMTS13 (A Disintegrin-like And Metalloprotease
domain with ThromboSpondin type-1 motif, member 13),
spontaneous microthrombi are formed leading to the rare
but severe disorder thrombotic thrombocytopenic purpura
(TTP) [1]. ADAMTS13 deficiency prevents trimming of
ultra-large (UL) von Willebrand factor (VWF) multimers.
These UL multimers spontaneously interact with platelets
and form aggregates that obstruct blood vessels in multi-
ple organs, resulting in microvascular thrombosis, severe
thrombocytopenia, and hemolytic anemia [1,2]. In the
majority of TTP patients, ADAMTS13 deficiency is
acquired due to anti-ADAMTS13 antibodies either neu-
tralizing the enzyme’s activity or accelerating its clearance
[3,4]. Fewer patients have congenital TTP, or Upshaw–
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Schulman syndrome, defined by genetic mutations and
polymorphisms within the ADAMTS13 gene [5,6]. AD-
AMTS13 deficiency alone might not provoke TTP, as
some patients remain asymptomatic until early adulthood.
In these patients, a second hit or trigger such as acute
infections or pregnancy causes the onset of TTP [7].
ADAMTS13 is located on chromosome 9q34 and con-
sists of 29 exons [8,9]. More than 150 different mutations
(missense, nonsense, and splice site mutations; small dele-
tions and insertions) randomly distributed throughout the
ADAMTS13 gene have been reported so far [10]. To date,
approximately two-thirds of the congenital TTP patients
are compound heterozygous, while the remaining patients
bear homozygous ADAMTS13 mutations. In vitro char-
acterization of many of these ADAMTS13 mutations
revealed that the majority impaired protein secretion,
although mutations that also influence ADAMTS13 activ-
ity (e.g., p.Ser119Phe [11], p.Arg193Trp [12], p.Pro457Leu
[13], and p.Arg1060Trp [14]) have been reported [5]. Phe-
notypic consequences of these mutations have never been
tested in animal models. Such studies might nevertheless
provide valuable information on the contribution of
specific ADAMTS13 mutations to the pathophysiology
of TTP.
In this study, the genetic defect in a pregnancy-onset
TTP patient was identified to correctly diagnose her with
hereditary TTP. In addition, the expression and activity
of the recombinant mutant protein were evaluated in
vitro. Finally, we used a TTP mouse model in which
Adamts13–/– mice were triggered with recombinant
human VWF (rVWF) [15] [16] to study the effect of the
ADAMTS13 mutant on the pathophysiology of TTP.
Patient, materials, and methods
Case history
A now 41-year-old woman was initially referred to the
hospital in 2006 for hematological assessment following
two complicated pregnancies. Her first pregnancy at the
age of 31 was complicated by mild thrombocytopenia
detected at week 12 with severe intrauterine growth retar-
dation. HELPP (hemolysis, elevated liver enzymes, and a
low platelet count) syndrome was suspected, and medical
pregnancy termination was performed at week 17. During
her second pregnancy at the age of 34, abnormal uterine
artery Doppler waveforms were found at week 26. She
was admitted at week 28 for fetal monitoring. Fetal
growth stagnation and mild thrombocytopenia (platelet
count of 108 000 lL1) with biological signs of hemolysis
and microangiopathy (elevated lactate dehydrogenase lev-
els, reduced haptoglobin levels, but absence of schisto-
cytes) were confirmed. There was no disturbance of liver
enzymes, and proteinuria was absent. Treatment with
steroids was empirically initiated (methylprednisolone
1 mg kg1). Cesarean section was performed at week
28 with a platelet count of 48 000 lL1. Pathological
examination of the placenta revealed signs of chronic
anoxia. Postpartum, the platelet count decreased to
14 000 lL1 with clear signs of hemolysis and microangi-
opathy (schistocytes 4%, elevated lactate dehydrogenase,
low haptoglobin). Platelets then normalized within
10 days with steroids alone.
When she was tested in 2006, her platelet count was
normal. Complete thrombophilia workup was performed
but did not reveal any acquired or congenital abnormality
with the exception of a slight increase in factor VIII
(FVIII; 166%) and VWF (160% for the antigen and
168% for the activity measured by collagen binding
assay) levels. Because of her history of microangiopathy,
ADAMTS13 activity was measured (she was under remis-
sion at that time) and found to be < 8% (TECHNO-
ZYME ADAMTS13-activity ELISA; Technoclone,
Vienna, Austria), and no anti-ADAMTS13 antibodies
were detected in her plasma (mixing studies with normal
plasma using the TECHNOZYME ADAMTS13-activity
ELISA). There were no plasma samples available from
the period of her pregnancy to test for ADAMTS13 anti-
gen and activity levels. From the family history it became
clear that her mother had three pregnancies, two of which
were complicated by preeclampsia. There was, however,
no history suspicion of microangiopathy in any other
member of her family. Family screening for ADAMTS13
deficiency has not yet been feasible. Because of the clini-
cal expression and ADAMTS13 phenotype, the patient
was diagnosed with TTP. Mutation analysis of ADAM-
TS13 was performed in this study to confirm the diagno-
sis of hereditary TTP. Informed consent was obtained in
accordance with the Declaration of Helsinki.
Identification of the mutation
Genomic DNA was extracted from the peripheral leuko-
cytes from the patient using the salting out procedure as
described [17]. All 29 ADAMTS13 exons with exon–
intron boundaries were amplified by polymerase chain
reaction with primers as described elsewhere [18]. Prod-
ucts were sequenced in both directions, and sequencing
reactions were outsourced (GATC Biotech AG, Kon-
stanz, Germany).
Expression of recombinant wild-type and p.D187H
ADAMTS13
The identified missense mutation p.D187H was intro-
duced in the pcDNA6.1 ADAMTS13 expression vector
using the QuickChangeTM XL Site Directed Mutagenesis
Kit (Stratagene, La Jolla, CA, USA). Constructs were
sequenced (GATC Biotech AG), and sufficient amounts
of both ADAMTS13 wild-type (WT) and D187H DNA
plasmids were obtained using the Qiagen Plasmid Mega
Kit (Qiagen, Venlo, The Netherlands). Human embryonic
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kidney (HEK) 293T cells were stably transfected with
plasmid DNA encoding either WT or mutant D187H
ADAMTS13 using FuGENE HD transfection reagent
(Roche Applied Science, Penzberg, Germany), and cells
were selected on Blasticidin (Invitrogen, Carlsbad, CA,
USA). Recombinant proteins were produced and partially
purified, and concentrations were determined in the AD-
AMTS13:Ag ELISA [19].
Transient (co)transfections were performed to study
protein expression under heterozygous WT/D187H,
homozygous WT, or homozygous D187H conditions.
Transfection efficiency was controlled by the addition of
pmaxGFP (Lonza, San Diego, CA, USA) [20]. Briefly,
HEK293T cells were grown in Dulbecco’s modified Eagle
medium (DMEM; ATCC, Manassas, VA, USA) with
10% FCS and 1% P/S/F (Invitrogen) until 60–80% con-
fluency. Cells were transfected using jetPRIMETM trans-
fection reagent and a total of 4 lg plasmid DNA in
jetPRIMETM reaction buffer (VWR International, Rad-
nor, PA, USA). Plasmid DNA was a mixture of WT/
D187H/pmaxGFP DNA (1.8/1.8/0.4 lg), WT/
pmaxGFP DNA (3.6/0.4 lg), or D187H/pmaxGFP
DNA (3.6/0.4 lg). Expression was done in DMEM con-
taining 1% P/S/F. Forty-eight hours after transfection,
green fluorescent protein (GFP)-expressing cells were
visualized using a Nikon eclipse TE200 inverted fluores-
cence microscope (Nikon Instruments, Melville, NY,
USA) to determine transfection efficiency. One hundred
cells were randomly selected, and the number of fluores-
cent cells among these hundred cells was determined.
Expression medium was harvested, and expression levels
of WT and p.D187H ADAMTS13 were determined using
the ADAMTS13:Ag ELISA [19].
ADAMTS13 activity tests
Activities of ADAMTS13 WT and p.D187H were evalu-
ated using the fluorescent resonance energy transfer
(FRET) assay with the fluorescent FRETS-VWF73 sub-
strate (Peptides International; Louisville, KY, USA) as
described. Briefly, recombinant ADAMTS13 (0.5 nmol
L1) or transgene mADAMTS13 present in plasma
(30 lL) were incubated with 2 lmol L1 FRETS-VWF73
in a HEPES-buffered saline solution (50 mmol L1 HE-
PES, 5 mmol L1 CaCl2, 1 lmol L
1 ZnCl2, 150 mmol
L1 NaCl, pH 7.4 [HBS]), containing 1 mg mL1 bovine
serum albumin (Sigma, St Louis, MO, USA). Digestion
of FRETS-VWF73 by recombinant WT or p.D187H AD-
AMTS13 or transgene plasma mADAMTS13 generated a
fluorescent signal that was measured using the FLUOstar
OPTIMA reader (BMG Labtech GmbH, Offenburg, Ger-
many). One hundred cycles of 150 s or 40 cycles of 300 s
were measured using excitation at 355 nm and emission
at 460 nm. Fluorescent intensities were depicted in func-
tion of time. The slope of the resulting curve was used as
a measure for enzyme activity. Activity was represented
relative to normal human pooled plasma (NHP) or nor-
mal murine pooled plasma (NMP) (100%) [11,21].
To determine kinetic parameters of recombinant WT
and p.D187H ADAMTS13, varying concentrations of
ADAMTS13 (ranging from 0.1 to 10 nmol L1) were
incubated with 2 lmol L1 FRETS-VWF73. The increase
in fluorescence in function of time equals the rate of the
reaction. Concentrations for WT and p.D187H ADAM-
TS13 resulting in measurable enzyme activities were used
to determine the catalytic efficiency (kcat/KM). Therefore,
a constant concentration of ADAMTS13 (1 nmol L1
WT and 10 nmol L1 p.D187H) was incubated with 10
different concentrations of FRETS-VWF73 (ranging from
0.01 lmol L1 to 10 lmol L1). The rate of these 10 dif-
ferent reactions (dF/dt) was plotted in function of the
substrate concentration. dF/dt was converted to d[P]/dt
by determining the change in fluorescence which corre-
sponds to complete turnover of the substrate. The curve
was fitted to the Michaelis–Menten equation and Kcat/Km
was calculated using PRISM Version 5 software (GraphPad
Software, San Diego, CA, USA) [11,21].
Cleavage of platelet-decorated VWF strings in flow was
evaluated as previously described [22]. Briefly, blood out-
growth endothelial cells (BOECs) were stimulated with
25 lmol L1 histamine (Sigma) for 10 min and perfused
with fluorescently labeled (100 nmol L1 3,30-dihexyloxa-
carbocyanine iodide [Dioc6]; Invitrogen) washed platelets
at a shear rate of 250 s1 for 60 s, followed by perfusion
with HBS with or without ADAMTS13 WT or p.D187H
(25 nmol L1) for an additional 360 s. Perfusion with
HBS alone and ADAMTS13 preincubated for 10 min
with the inhibitory anti-ADAMTS13 antibody 3H9
(67 nmol L1) served as negative controls. BOEC-
anchored platelet-decorated VWF strings were visualized
using a Nikon eclipse TE200 inverted fluorescence micro-
scope (Nikon instruments), equipped with a 920 objective
and connected to a Hamamatsu CCD camera (ORCA-
R2; Hamamatsu Photonics, Hamamatsu city, Japan). Vid-
eos were recorded using HCIMAGE software (Hamamatsu
Photonics). Removal of all VWF strings in one view field
was followed in function of time and cleavage events,
which represent ADAMTS13 activity, were counted.
Experimental values were compared with the average
activity level obtained, using WT ADAMTS13, which
was set at 100% (n = 5).
Modeling of the mutated ADAMTS13 Ca2+-binding site
An in-depth structural analysis of the ADAMTS13
p.D187H mutation was performed starting with the AD-
AMTS13 homology model we published previously [11].
A high-affinity Ca2+-binding site involving D182 or
E184, D187, and E212 was identified by Gardner et al.
[23]. Based on these Ca2+-coordinating amino acids, a
homologous X-ray crystal structure was found in AD-
AMTS5 (PDB: 3HY7), containing a Ca2+ ion bound in a
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cavity similar to the predicted site in ADAMTS13 [24].
We optimized the three-dimensional structure of the
ADAMTS13 binding site (residues I178–V195 and T211–
L218) using the conformational search module in the
Molecular Operating Environment (MOE) package ver-
sion 2012.10 (Chemical Computing Group Inc., Montreal,
Quebec, Canada). This generated 1600 different confor-
mations, grouped in 57 clusters based on root-mean-
square deviation after fitting and visually inspected to
select a putative ADAMTS13 Ca2+-binding model. The
ADAMTS13 p.D187H mutation was introduced with the
mutagenesis module of the PYMOL modeling software
package version 1.5.0.4 (PyMOL Molecular Graphics Sys-
tem, Schr€odinger, LLC). A 2-ns molecular dynamics
(MD) simulation was performed with the GROMACS
4.6.5 package to test the stability of the homology models
in both ADAMTS13 WT and the p.D187H mutant [25].
Construction of a murine p.D187H ADAMTS13 expression
vector
cDNA encoding WT mADAMTS13 was amplified from
pcDNA6.1-mADAMTS13-WT [26] using Phusion High
Fidelity DNA polymerase (New England BioLabs, Ips-
wich, MA, USA) and primers flanking the desired region.
The mADAMTS13 polymerase chain reaction product
was ligated into the pBS-II-SK-HCRHPi expression vec-
tor containing a liver specific promoter (HCRHPi: human
a1-anti–trypsin promoter, and a truncated 1.4-kb human
FIX intron A [27]) using T4 DNA ligase (Roche Applied
Science) resulting in the pBS-II-SK-HCRHPi-mADA-
MTS13 WT construct. The p.D187H missense mutation
was introduced into the pBS-II-SK-HCRHPi mADA-
MTS13 WT expression vector using the QuickchangeTM II
XL Site Directed Mutagenesis Kit (Stratagene). Both con-
structs were sequenced (GATC Biotech AG), and suffi-
cient amounts of both mADAMTS13 WT and D187H
DNA plasmids were obtained using the Qiagen Plasmid
Mega Kit (Qiagen).
Murine TTP model
Adamts13–/– mice [28] (4–8 weeks, weighing 15–20 g) were
hydrodynamically injected with a total of 50 lg expres-
sion plasmids [27], either pBS-II-SK-HCRHPi mADA-
MTS13 WT, pBS-II-SK-HCRHPi mADAMTS13 D187H,
or an equal mixture (i.e. 2 9 25 lg) of both, to obtain
homozygous or heterozygous in vivo expression of WT
and p.D187H mADAMTS13. Three days later, TTP was
induced in these mice by injecting them with a single
bolus injection of 2000 rVWF ristocetin cofactor units
(rVWF:RCoU) per kg body weight of rVWF essentially
as described [15] but with rVWF injected retro-orbitally.
As controls, Adamts13–/– mice were hydrodynamically
injected with 0.9% NaCl followed by rVWF or PBS injec-
tion. Blood samples were collected on 3.8% trisodium cit-
rate 24 hours after rVWF injection and analyzed for
platelet counts using a Hemavet hematology system
(Drew Scientific Inc., Dallas, TX, USA). Plasma was
taken to determine mADAMTS13 antigen and activity
levels by an in-house developed mADAMTS13:Ag sand-
wich ELISA and FRETS-VWF73 assay, respectively. All
animal experiments were performed in accordance with
protocols approved by the Institutional Animal Care and
Use Committee of the KU Leuven (Belgium).
mADAMTS13:Ag ELISA
A 96-well microtiter plate was coated overnight with the
in-house developed murine anti-mADAMTS13 monoclo-
nal antibody 20A10 at 5 lg mL1 in PBS. After blocking,
plasma was diluted in PBS, 0.3% (m/v) skimmed milk,
and the plate was incubated at 37 °C for 1 h. An in-
house developed polyclonal rabbit anti-mADAMTS13
antibody was diluted in PBS, 0.3% (m/v) skimmed milk
to a final concentration of 5 lg mL1 and incubated for
1 hour. Bound antibody was detected with horseradish
peroxidase–labeled goat anti-rabbit antibody (Jackson
Immunoresearch Laboratories Inc., West Grove, PA,
USA) (1:25 000 in dilution buffer). Antibody binding was
detected as described here earlier. NMP was used as a ref-
erence.
Statistical analysis
Data are given as mean  SD. All data were analyzed
using PRISM Version 5 software (GraphPad Software).
Mean values were compared using the one-way or
two-way ANOVA followed by the Bonferroni multiple com-
parison post-test. A probability of < 0.05 was taken as
significant for rejection of null hypothesis.
Results
Heterozygous mutation p.D187H identified in the
ADAMTS13 metalloprotease domain
In 2014, when the patient was in remission, her ADAM-
TS13 antigen and activity were assayed again with our in-
house developed ADAMTS13 antigen assay [19] and the
FRETS-VWF73 assay, respectively. Her ADAMTS13
antigen levels were severely reduced (17  1%, n = 3,
compared with NHP), and her ADAMTS13 activity was
below the detection limit of the assay (< 0.5%, n = 3
compared with NHP). We next studied the presence of a
possible genetic defect in ADAMTS13. Sequence analysis
of all 29 exons of her ADAMTS13 gene revealed the pres-
ence of a heterozygous c.559G>C mutation in exon 6.
This missense mutation changes D 187 to H (p.D187H)
in the metalloprotease domain of ADAMTS13. Interest-
ingly, D187 is part of the high affinity Ca2+-binding site,
which is situated close to the active site cleft [23].
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The p.D187H mutation attenuates ADAMTS13 activity in
vitro and induces unstable Ca2+ binding
The p.D187H mutation reduces the catalytic efficiency of
ADAMTS13 To determine the catalytic efficiency (kcat/
Km) of p.D187H and compare it with that of WT AD-
AMTS13, a FRETS-VWF73 kinetic assay was performed.
Analysis of product turnover in function of substrate con-
centration revealed comparable Km values for p.D187H
and WT ADAMTS13 (0.93  0.76 and 0.92  0.77 lmol
L1, n = 4 respectively), indicating that binding affinity
was similar. However, the kcat for p.D187H was severely
reduced compared with WT ADAMTS13 (0.03 
0.03 and 0.30  0.11 s1, n = 4 respectively). Hence, the
catalytic efficiency (kcat/KM) of p.D187H was 11-fold
lower (11.0  3.6, n = 4) than that of WT ADAMTS13,
demonstrating that the mutation negatively affects
substrate turnover and/or product release.
The p.D187H mutation impairs proteolysis of VWF strings
under flow conditions The activity of p.D187H ADAM-
TS13 was also studied in a more physiological assay in
which the disappearance of platelet-decorated VWF
strings anchored to stimulated endothelial cells under flow
conditions was followed in function of time. A decreased
activity of p.D187H ADAMTS13 (54.4  9.1%, n = 5)
compared with WT ADAMTS13 (100.0  7.1%, n = 5,
with the mean value of WT ADAMTS13 activity set as
100%) was observed (Fig. 1A). Background activity, eval-
uated by adding the inhibitory anti-ADAMTS13 antibody
3H9 to WT ADAMTS13 (23.1  5.7%, n = 5) and using
HBS alone (17.8  7.5%, n = 5) was similar as described
previously [22].
The p.D187H mutation induces unstable binding of
Ca2+ Because it was previously described that D187
plays an important role in Ca2+ binding [23], a homology
model of ADAMTS13 was made to study the influence of
the p.D187H mutation on Ca2+ binding. Our constructed
ADAMTS13 Ca2+-binding model indicated that apart
from residues D182, E184, H187, and E212 [23], a water
molecule might be essential for proper Ca2+ binding as
well (Fig. 1B). MD simulations (2 ns) for WT ADAM-
TS13 suggested that the predicted Ca2+-binding site was
stable as the position of the Ca2+ ion coordinated by the
negatively charged amino acids and the water molecule
remained unchanged during the entire simulation (Fig. 1B
and Video S1). Using p.D187H ADAMTS13, however,
MD simulations showed that the Ca2+-binding site
deformed due to extensive movement of the loop contain-
ing the p.D187H mutation, ultimately leading to a dis-
placement of the bound water molecule and considerable
fluctuations in the Ca2+ ion position compared with the
WT ADAMTS13 Ca2+-binding model (Fig. 1B and
Video S1). Hence, these data suggest that the p.D187H
mutation gives rise to a decreased binding affinity for
Ca2+, thereby confirming previously published data on
the importance of D187 in Ca2+ binding.
The p.D187H mutation impairs secretion in vitro
The effect of the p.D187H mutation on protein secretion
was tested in vitro by performing transient transfections
of heterologous HEK293T cells with both WT and
p.D187H ADAMTS13 expression plasmids. A GFP-
expressing plasmid was added in all experiments to deter-
mine transfection efficiency, which was similar for both
the homozygous WT (32.6  5.9%, n = 3) and p.D187H
(26.1  1.4%, n = 3, P > 0.05) conditions. Interestingly,
relative ADAMTS13 antigen levels were significantly
reduced in the homozygous p.D187H (40.4  9.3%,
n = 3) compared with the WT condition (100  14.9%,
n = 3, P < 0.01) (Fig. 2A), implying that p.D187H nega-
tively influences protein secretion. In line with the data
obtained with FRETS and flow assays together with the
reduced expression levels of p.D187H, the activity of the
transiently expressed homozygous p.D187H enzyme
(20.2  0.7%, n = 3) was significantly reduced compared
with that of WT (100  4.6%, n = 3, P < 0.001, Fig. 2B).
Because the patient is heterozygous for the mutation, we
also investigated expression levels of WT/p.D187H pro-
teins. Transfection efficiency of heterozygous WT/
p.D187H ADAMTS13 plasmids (24.6  2.5%, n = 3)
was also similar (P > 0.05) to those of homozygous WT
or p.D187H plasmids. Interestingly, heterozygous WT/
p.D187H expression levels (53.8  15.5%, n = 3) were
significantly lower than those of the WT condition
(P < 0.01) but comparable with those of p.D187H
(P > 0.05, Fig. 2A). As expected, the activity of heterozy-
gous WT/p.D187H ADAMTS13 (45.8  2.7%, n = 3)
was also significantly lower than that of WT (P < 0.001,
Fig. 2B). Hence, transient transfection experiments show
that ADAMTS13 expression (53.8  15.5%) and activity
(45.8  2.7%) levels of the heterozygous WT/p.D187H
condition did not entirely mimic the patients’ situation
where only 8% ADAMS13 activity was measured. These
data suggest that another unidentified mutation might be
present in, for example, the promoter region of the AD-
AMTS13 gene of our proposita.
WT but not p.D187H ADAMTS13 rescues the TTP
phenotype of Adamts13–/– mice
We finally investigated whether the homozygous p.D187H
mutation could induce TTP in vivo by making Adamts13–/
– mice transgenic for the p.D187H mutant using the tech-
nique of hydrodynamic injection [27] and triggering the
mice with rVWF [15]. The heterozygous condition was not
investigated in vivo as our transient transfection experi-
ments showed that this situation did not entirely mimic
the patients’ condition. First, plasmids were generated
expressing WT and p.D187H mADAMTS13 under
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Fig. 1. The p.D187H mutation partially inhibits ADAMTS13 activity in vitro. (A) Stimulated endothelial cells were perfused with 3,30-dihexy-
loxacarbocyanine iodide (DIOC)-labeled washed platelets at a shear rate of 250 s1 for 60 s. Resulting platelet-decorated von Willebrand factor
strings were perfused with HEPES buffer (HBS) without (control) or with wild-type (WT) or p.D187H ADAMTS13 (25 nmol L–1) for an addi-
tional 360 s. Control reactions were performed with WT ADAMTS13 in the presence of the inhibitory anti-ADAMTS13 monoclonal antibody
3H9 (67 nmol L–1) or in the absence of ADAMTS13 (HBS buffer). Mean of WT data was set as 100%. Data are represented as mean  SD
(n = 5, ***P < 0.001, one-way ANOVA). (B) Molecular modeling of the ADAMTS13 metalloprotease domain shows unstable Ca2+ binding in
the p.D187H mutant. Representation of the ADAMTS13 metalloprotease domain homology model and, more specifically, the proposed high-
affinity Ca2+-binding site. The Ca2+ (blue sphere)-binding site is formed by residues D182, E184, D187, and E212 (green sticks) and a water
molecule (red/white sphere). Molecular dynamic simulation reveals a local unfolding due to electrostatic repulsion. Images at the start, middle,
and end of the simulation are shown. Mutation of residue p.D187 to histidine leads to a deformed structure at the Ca2+-binding site (see mid-
dle and end images, and Video S1) and hence negatively influences the stability of Ca2+ binding.
© 2014 International Society on Thrombosis and Haemostasis
288 E. De Cock et al
control of a liver-specific promoter (HCRHPi). Next,
D187H and WT mADAMTS13 expression plasmids were
hydrodynamically injected in Adamts13–/– mice. In vivo
expression of homozygous p.D187H mAdamts13 was sig-
nificantly reduced (143  78%, n = 11, P < 0.001) com-
pared with homozygous WT mAdamts13 (985  452%,
n = 7) (Fig. 3A), confirming that the p.D187H mutation
indeed affects protein secretion. As expected, the p.D187H
activity (6.3  4.5%, n = 11 was significantly reduced
compared with WT (76.7  10.6%, n = 7, P < 0.001)
(Fig. 3B).
Mice were subsequently triggered with 2000 U kg1
rVWF, and the degree of thrombocytopenia was mea-
sured, which was used as a parameter for the TTP pheno-
type [15]. Adamts13–/– mice expressing WT
mADAMTS13 and triggered with rVWF did not develop
TTP as their platelet counts (541  55 9 103 lL1,
n = 7, Fig. 3C, WT) did not differ from those of control
Adamts13–/– mice that were not expressing ADAMTS13
and were not triggered with rVWF (487  51 9
103 lL1, n = 8, Fig. 3C, C2). In contrast, Adamts13–/–
hydrodynamically injected with 0.9% NaCl and triggered
with rVWF did develop TTP (189  80 9 103 lL1,
n = 9, Fig. 3C, C1; P < 0.001 vs. WT and C2). Interest-
ingly however, mADAMTS13 p.D187H could not prevent
the TTP phenotype as hydrodynamic injection of the cor-
responding expression plasmid resulted in a significant
drop in platelet counts (309  79 9 103 lL1, n = 11,
Fig. 3C, p.D187H) compared with control mice not trig-
gered with rVWF (487  51 9 103 lL1, n = 8,
P < 0.001, Fig. 3C, C2) and mice injected with WT
mADAMTS13 expression plasmid and triggered with
rVWF (541  55 9 103 lL1, n = 7, Fig. 3C, WT).
These data indicate that both the reduced expression of
p.D187H (Fig. 3A) and its reduced activity (Fig. 3B) can
induce a TTP phenotype in vivo. In conclusion, the
p.D187H mutation contributes to TTP in mice under
homozygous conditions.
Discussion
In this study, we investigated whether the ADAMTS13
p.D187H mutation identified in a patient with pregnancy-
onset TTP affects protein secretion and activity in vitro
and whether this mutation could account for a TTP phe-
notype in vivo. To the best of our knowledge, the
p.D187H mutation has never been associated with TTP.
Recently, however, p.D187H was found as one of the rare
coding SNPs in patients with deep vein thrombosis [29].
We show here that the p.D187H mutation reduced the
catalytic efficiency of ADAMTS13 by 11-fold. Our data
strongly corroborate with the finding that D187 was part
of the high-affinity Ca2+ binding site of ADAMTS13 and
crucial for enzyme activity as a D187A mutant had a 10-
fold reduced kcat/KM compared with WT ADAMTS13
[23,30]. The p.D187H mutant enzyme was, moreover, less
effective in cleaving full-length VWF under flow condi-
tions. Further, molecular simulations demonstrated that
the p.D187H mutation induces unstable Ca2+ binding,
which is in line with the reduced activity of the mutant
enzyme. The p.D187H mutation not only affected
ADAMTS13 activity but also negatively influenced pro-
tein secretion as demonstrated by a severe reduction
(60%) in p.D187H protein levels in the expression med-
ium of transiently transfected HEK293T cells compared
with WT. Interestingly, however, transfection of the
p.D187H mutant under heterozygous conditions resulted
in ADAMTS13 antigen and activity levels of 53.8% and
45.8%, respectively, which was not in agreement with
the heterozygous p.D187H condition observed in our
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proposita where ADAMTS13 antigen and activity levels
were 17  1% and < 0.5%, respectively. These data sug-
gest that the patient might be compound heterozygous
for another, yet unidentified mutation probably in the
ADAMTS13 promoter region or introns, as they were not
sequenced in this study. On the other hand, although the
D187H mutation did not alter a glycosylation site in the
mutant protein, differences in glycosylation between
recombinant ADAMTS13 (expressed in the HEK293T
cells) and plasma ADAMTS13 (mainly produced by stel-
late liver cells) might explain in part the observed differ-
ences in ADAMTS13 antigen levels of the p.D187H
mutant in culture medium and plasma (53.8% and 17%,
respectively). It was recently reported that not all N142
and N146 residues were glycosylated in plasma VWF,
while these sites always contained N-linked carbohydrates
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in recombinant ADAMTS13 expressed in HEK293 cells
[31,32]. Because N-linked glycans provide stability to a
protein, plasma ADAMTS13 might be less stable than
recombinant ADAMTS13. Therefore, a combination of
the absence of carbohydrates on N142/N146 in plasma
ADAMST13 with the presence of the D187H mutation in
the Ca2+-binding site, which might also reduce protein
stability, might lead to a more profound reduction in
secretion of plasma p.D187H than of recombinant
p.D187H. Nevertheless, by studying this novel p.D187H
ADAMTS13 mutation in vivo in a mouse model of TTP
[15], we could clearly demonstrate that the homozygous
p.D187H mutation severely impairs ADAMTS13 secre-
tion and activity, which were associated with TTP in
these animals.
In conclusion, we showed that the p.D187H mutation
modulates ADAMTS13 expression and reduces ADAM-
TS13 activity by affecting the Ca2+-binding site. Using
the in vivo mouse model, we could demonstrate that the
homozygous ADAMTS13 p.D187H can indeed induce
TTP when mice are triggered with rVWF. Whether our
proposita is compound heterozygous for another yet
unidentified ADAMTS13 mutation remains to be deter-
mined.
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